Myeloid Cancer Gene Variant Curation Expert Panel
Official title: Myeloid Malignancy Variant Curation Expert Panel
Funded at Northwestern University · NIH-11384370 · Data updated 2026-11-12
A patient-facing group creates and shares trusted rules for interpreting genetic variants that raise the risk of blood cancers, helping families understand their test results.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | April 20, 2021 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $214,235 |
| NIH project number | 5U24CA258118-07 |
| Project ID | NIH-11384370 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with or at risk for myeloid malignancies who have or may have germline genetic variants in RUNX1, DDX41, GATA2, ANKRD26, ETV6, CEBPA, SAMD9/SAMD9L, TERT/TERC, or related genes.
✕Less likely to help
Patients without germline variants in the target genes may not directly benefit from the variant-curation outcomes.
What this research studies
This grant supports a team at Northwestern University that develops and updates guidelines for labeling genetic variants linked to blood cancer risk. The work focuses on germline predisposition genes such as RUNX1, DDX41, GATA2 and others, so clinicians can classify variants accurately across patients. By collaborating with patient organizations, the panel aims to connect families with clear information and resources related to inherited risks. The project builds on prior work and plans to extend variant-curation rules to additional genes tied to myeloid malignancies.
Why it matters
Potential benefit: If successful, it could lead to more accurate genetic interpretations for patients and families, aiding diagnosis, risk assessment, and informed medical decisions.
How similar studies have gone: Previous efforts by the MM-VCEP established standardized RUNX1 variant rules and are used internationally, showing practical impact of this approach.
Where this research is happening
-
Northwestern University
Chicago, United States Active
Researchers
- Principal investigator: Godley, Lucy Ann — Northwestern University
- Study coordinator: Godley, Lucy Ann
Related research
Other NIH-funded projects on the same topics.
-
Genetic variant review team for myeloid blood cancers
Experts are reviewing inherited genetic changes that raise the risk of myeloid blood cancers so patients and families get clearer test results and care guidance.
-
Creating a bone marrow model to study a genetic platelet disorder and its cancer risks
This study is looking at a rare genetic condition that affects blood platelets and can increase the risk of blood cancers, and it's for people with this condition; the researchers want to create a mini version of bone marrow to better understand the disease and find new ways to help reduce the risk of leukemia.
-
Understanding genetic risks for blood cancers
This study is looking at specific genetic changes that might make people more likely to develop certain blood cancers, and it aims to help patients and their families understand their risks better and find more personalized ways to manage their health.
-
Detecting cancer risk and treatment response in NF1 nerve tumors using cfDNA markers
A doctor-led study will test blood-based DNA markers to detect when NF1-related nerve tumors become malignant and to monitor how well treatment is working.
-
Epigenetic Basis for Controlling Aggressive IDH-Mutant Gliomas
Aims to understand and shape the epigenetic changes in IDH-mutant brain tumors to restrain their growth, which could lead to new, targeted treatment options for patients.
-
US–East Africa center to prevent and detect virus-linked cancers in people with HIV
This program builds a US–East Africa research network to train local investigators and improve prevention, earlier detection, and faster connection to care for virus-related cancers in people with HIV.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.